当前位置： SCI文献检索 > VACCINE期刊下所有文献 > Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C.

Abstract：

:A conjugate vaccine against meningococcus A and C was prepared using the non-toxic mutant of diphtheria toxin CRM 197 as a carrier protein. Capsular polysaccharides of Neisseria meningitidis group A and C were hydrolysed and the resulting oligosaccharides were then coupled to CRM 197 in order to obtain conjugates with a carbohydrate content of 25-30%. The final vaccine that contained 11 micrograms of each oligosaccharide and 88 micrograms of CRM 197 was used to immunize mice and rabbits. After the preclinical studies which showed that the vaccine was safe and immunogenic in animal models, a pilot phase 1 clinical trial, blind versus placebo, was performed on adult volunteers. The difference between the incidence of adverse reactions associated with vaccine and placebo administration was not statistically significant. All the volunteers who received the vaccine had a significant increase in antibodies to group A and C meningococcal capsular polysaccharides after the first dose.

journal_name

Vaccine

journal_title

Vaccine

authors

Costantino P,Viti S,Podda A,Velmonte MA,Nencioni L,Rappuoli R

doi

10.1016/0264-410x(92)90091-w

subject

Has Abstract

pub_date

1992-01-01 00:00:00

pages

691-8

issue

10

eissn

0264-410X

issn

1873-2518

pii

0264-410X(92)90091-W

journal_volume

10

pub_type

临床试验,杂志文章

相关文献

VACCINE文献大全
  • Changes in prevalence of ovine paratuberculosis following vaccination with Gudair®: Results of a longitudinal study conducted over a decade.

    abstract：:Since its registration in 2002, Gudair® vaccine has become the key tool for managing paratuberculosis in sheep in Australia. This study was conducted to evaluate its effectiveness in reducing paratuberculosis prevalence in 12 flocks over more than one decade. Flocks with variable initial prevalence (5, 4 and 3 with lo...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.08.064

    authors： Dhand NK,Eppleston J,Whittington RJ,Windsor PA

    更新日期：2016-09-30 00:00:00

  • Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes.

    abstract：:The divergence of regulatory requirements and processes in developing and emerging countries contributes to hamper vaccines' registration, and therefore delay access to high-quality, safe and efficacious vaccines for their respective populations. This report focuses on providing insights on the heterogeneity of regist...

    journal_title：Vaccine

    pub_type：

    doi：10.1016/j.vaccine.2018.03.049

    authors： Dellepiane N,Pagliusi S,Registration Experts Working Group.

    更新日期：2018-06-07 00:00:00

  • Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia.

    abstract：:Although vaccination against Streptococcus pneumoniae (S. pneumoniae) and Haemophilus influenzae type b (Hib) is recommended for immunocompromised patients, such as patients with B-cell chronic lymphocytic leukaemia (B-CLL), its protective effect is questionable. We studied antibody responses to pneumococcal polysacch...

    journal_title：Vaccine

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0264-410x(00)00409-6

    authors： Hartkamp A,Mulder AH,Rijkers GT,van Velzen-Blad H,Biesma DH

    更新日期：2001-02-08 00:00:00

  • Prophylaxis of experimental HTLV-I infection in cynomolgus monkeys by passive immunization.

    abstract：:The protective effect of purified human immunoglobulin against human T-cell leukaemia virus type I (HTLV-I), designated ATLIG on HTLV-I infection was examined in cynomolgus monkeys (Macaca fascicularis) as a preclinical study. Passive immunization of ATLIG 24 h before challenging HTLV-I protected the monkeys from HTLV...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(97)00055-8

    authors： Akari H,Suzuki T,Ikeda K,Hoshino H,Tomono T,Murotsuka T,Terao K,Ito H,Yoshikawa Y

    更新日期：1997-08-01 00:00:00

  • Assessing vaccine potency using TCRmimic antibodies.

    abstract：:Dendritic cells (DCs) are highly specialized antigen-presenting cells of the immune system that are efficient at presenting peptide-antigen for the activation of T cells and are often the cell type of choice for vaccine targeting by virtue of high expression levels of MHC and costimulatory molecules. Since the level o...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.02.025

    authors： Neethling FA,Ramakrishna V,Keler T,Buchli R,Woodburn T,Weidanz JA

    更新日期：2008-06-13 00:00:00

  • Overview of rabies post-exposure prophylaxis access, procurement and distribution in selected countries in Asia and Africa, 2017-2018.

    abstract：BACKGROUND:Rabies is a neglected zoonotic disease with a global burden of approximately 59,000 human deaths a year. Once clinical symptoms appear, rabies is almost invariably fatal; however, with timely and appropriate post-exposure prophylaxis (PEP) consisting of wound washing, vaccine, and in some cases rabies immuno...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2019.04.024

    authors： Sreenivasan N,Li A,Shiferaw M,Tran CH,Wallace R,Blanton J,Knopf L,Abela-Ridder B,Hyde T,Working group on Rabies PEP logistics.

    更新日期：2019-10-03 00:00:00

  • Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010-2018.

    abstract：:Pneumococcal meningitis in the African meningitis belt is primarily caused by Streptococcus pneumoniae serotype 1, a serotype contained in the 13-valent pneumococcal conjugate vaccine (PCV13). In 2014, Niger introduced PCV13 with doses given at 6, 10, and 14 weeks of age. We leveraged existing meningitis surveillance ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.04.009

    authors： Ousmane S,Kobayashi M,Seidou I,Issaka B,Sharpley S,Farrar JL,Whitney CG,Ouattara M

    更新日期：2020-05-13 00:00:00

  • MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice.

    abstract：BACKGROUND:By the time clinical symptoms of Alzheimer's disease (AD) manifest in patients there is already substantial tau pathology in the brain. Recent evidence also suggests that tau pathology can become self-propagating, further accelerating disease progression. Over the last decade several groups have tested the e...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2017.03.020

    authors： Davtyan H,Chen WW,Zagorski K,Davis J,Petrushina I,Kazarian K,Cribbs DH,Agadjanyan MG,Blurton-Jones M,Ghochikyan A

    更新日期：2017-04-11 00:00:00

  • Plant heat shock protein 90 as carrier-adjuvant for immunization against a reporter antigen.

    abstract：:Here, we evaluated the modulation of the immune response induced by Hsp90 of Nicotiana benthamiana (NbHsp90.3) against the Maltose Binding Protein (MBP) as a reporter antigen. Equimolar quantities of recombinant proteins were administered in mice as follows: MBP alone (MBP group), a mixture of MBP and rNbHsp90.3 (MBP+...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.09.047

    authors： Corigliano MG,Fenoy I,Sander V,Maglioco A,Goldman A,Clemente M

    更新日期：2013-12-02 00:00:00

  • Reduction of foot-and-mouth disease (FMD) virus load in nasal excretions, saliva and exhaled air of vaccinated pigs following direct contact challenge.

    abstract：:In future, a policy of "vaccinate-to-live" may be included in the repertoire of foot-and-mouth disease (FMD) control measures and in support of this approach, we have investigated the hypothesis that vaccine-induced reduction in virus replication and excretion from pigs can be correlated to the severity of clinical si...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2007.08.058

    authors： Parida S,Fleming L,Oh Y,Mahapatra M,Hamblin P,Gloster J,Doel C,Gubbins S,Paton DJ

    更新日期：2007-11-07 00:00:00

  • Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.

    abstract：BACKGROUND:Bacillus Calmette-Guérin (BCG) vaccination is a widely-used public health intervention for tuberculosis (TB) control. In Taiwan, like other intermediate TB burden settings, steadily declining TB incidence raises important questions on whether universal BCG vaccination should be discontinued. Recent surveys o...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2018.08.019

    authors： Fu H,Lin HH,Hallett TB,Arinaminpathy N

    更新日期：2018-09-18 00:00:00

  • Delayed progression of murine AIDS in C57BL/6 mice pre-immunized with a highly antigenic 10-mer peptide encoded by the murine AIDS defective virus gag p12 gene.

    abstract：:C57BL/6 (B6) mice were immunized with a highly antigenic 10-mer peptide (P12-10), which is encoded by the murine AIDS (MAIDS) defective virus gag p12 gene, emulsified in incomplete Freund's adjuvant (ICFA). One week later, the mice were inoculated with the MAIDS virus to see if the immunization affects progression of ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(98)00082-6

    authors： Mizuochi T,Horino A,Uchida T

    更新日期：1998-12-01 00:00:00

  • Induction of cross-reactive HIV-1 specific antibody responses by engineered V1V2 immunogens with reduced conformational plasticity.

    abstract：:Antibodies against the HIV-1 V1V2 loops were the only correlate of reduced infection risk in the RV144 vaccine trial, highlighting the V1V2 loops as promising targets for vaccine design. The V1V2 loops are structurally plastic, exhibiting either an α-helix-coil or β-strand conformation. V1V2-specific antibodies may th...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2020.03.010

    authors： Lai JI,Eszterhas SK,Brooks SA,Guo C,Zolla-Pazner S,Seaman MS,Bailey-Kellogg C,Griswold KE,Ackerman ME

    更新日期：2020-04-16 00:00:00

  • Polio Eradication Initiative: Contribution to improved communicable diseases surveillance in WHO African region.

    abstract：INTRODUCTION:Since the launch of the Global Polio Eradication Initiative (GPEI) in 1988, there has been a tremendous progress in the reduction of cases of poliomyelitis. The world is on the verge of achieving global polio eradication and in May 2013, the 66th World Health Assembly endorsed the Polio Eradication and End...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2016.05.060

    authors： Mwengee W,Okeibunor J,Poy A,Shaba K,Mbulu Kinuani L,Minkoulou E,Yahaya A,Gaturuku P,Landoh DE,Nsubuga P,Salla M,Mihigo R,Mkanda P

    更新日期：2016-10-10 00:00:00

  • Peptide vaccination is superior to genetic vaccination using a recombineered bacteriophage λ subunit vaccine.

    abstract：:Genetic immunization holds promise as a vaccination method, but has so far proven ineffective in large primate and human trials. Herein, we examined the relative merits of genetic immunization and peptide immunization using bacteriophage λ. Bacteriophage λ has proven effective in immune challenge models using both imm...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.12.070

    authors： Thomas BS,Nishikawa S,Ito K,Chopra P,Sharma N,Evans DH,Tyrrell DL,Bathe OF,Rancourt DE

    更新日期：2012-02-01 00:00:00

  • Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention.

    abstract：BACKGROUND:Postherpetic neuralgia (PHN) occurs in 5-30% of individuals with herpes zoster (HZ) and is characterized by long-lasting pain. Zoster vaccine live (ZVL) is licensed for people 50 years and older to prevent HZ and PHN. This study evaluated vaccine effectiveness (VE) of ZVL against PHN. METHODS:We conducted a...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2019.07.004

    authors： Klein NP,Bartlett J,Fireman B,Marks MA,Hansen J,Lewis E,Aukes L,Saddier P

    更新日期：2019-08-23 00:00:00

  • Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate.

    abstract：:A devastating disease spread by mosquitoes with high-efficiency, malaria imposes an enormous burden for which no licensed vaccine currently exists. Although the genome complexity of the parasite has made vaccine development tenuous, an effective malaria vaccine would be a valuable tool for control, elimination and eve...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2011.06.052

    authors： Palacpac NM,Arisue N,Tougan T,Ishii KJ,Horii T

    更新日期：2011-08-11 00:00:00

  • Governments, off-patent vaccines, smallpox and universal childhood vaccination.

    abstract：:WHO is now celebrating more than 30 years of freedom from smallpox. What was originally seen as a victory over an ancient scourge can now be viewed as an epidemiologically driven programme to overcome governmental inertia and under-achievement in delivering an off-patent vaccine. Though efforts are accelerating global...

    journal_title：Vaccine

    pub_type： 社论

    doi：10.1016/j.vaccine.2009.08.006

    authors： Music S

    更新日期：2010-01-22 00:00:00

  • A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses.

    abstract：:Since the production of influenza vaccines is complicated by the continuous variation of these viruses, it would be desirable to develop vaccines that induce cross-protective immunity against influenza virus strains that circulate in subsequent winter epidemics. We have recently demonstrated that antibodies induced af...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(01)00262-6

    authors： Rimmelzwaan GF,Baars M,van Amerongen G,van Beek R,Osterhaus AD

    更新日期：2001-10-12 00:00:00

  • Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer.

    abstract：:ErbB-2 is associated with several solid tumours of which breast cancer is the commonest cancer in women worldwide. Though anti-ErbB-2 antibody appears to play a significant role in prevention and therapy, naturally occurring anti-ErbB-2 antibody associated with the cleaved ectodomain of overexpressed ErbB-2 self antig...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.10.077

    authors： Mukhopadhyay A,Dyring C,Stott DI

    更新日期：2014-02-12 00:00:00

  • Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity.

    abstract：:Development of effective new mucosal vaccine adjuvants has become a priority with the increase in emerging viral and bacterial pathogens. We previously reported that cationic liposomes complexed with non-coding plasmid DNA (CLDC) were effective parenteral vaccine adjuvants. However, little is known regarding the abili...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.05.009

    authors： Henderson A,Propst K,Kedl R,Dow S

    更新日期：2011-07-18 00:00:00

  • Cell culture attenuation eliminates rMd5ΔMeq-induced bursal and thymic atrophy and renders the mutant virus as an effective and safe vaccine against Marek's disease.

    abstract：:Marek's disease virus (MDV) encodes a basic leucine zipper oncoprotein, Meq, which structurally resembles jun/fos family of transcriptional activators. It has been clearly demonstrated that deletion of Meq results in loss of transformation and oncogenic capacity of MDV. The rMd5ΔMeq virus provided superior protection ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2012.05.043

    authors： Lee LF,Heidari M,Zhang H,Lupiani B,Reddy SM,Fadly A

    更新日期：2012-07-20 00:00:00

  • Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

    abstract：:We exploited the powerful adjuvant properties of cholera holotoxin (CT) to create a mucosally administered subunit vaccine against respiratory syncytial virus (RSV). A genetically detoxified mutant CT with an E to H substitution at amino acid 29 of the CT-A1 subunit (CT-E29H) was compared to wild type CT for toxicity ...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/s0264-410x(00)00058-x

    authors： Tebbey PW,Scheuer CA,Peek JA,Zhu D,LaPierre NA,Green BA,Phillips ED,Ibraghimov AR,Eldridge JH,Hancock GE

    更新日期：2000-06-01 00:00:00

  • Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

    abstract：:A HIV-1 tier system has been developed to categorize the various subtype viruses based on their sensitivity to vaccine-induced neutralizing antibodies (NAbs): tier 1 with greatest sensitivity, tier 2 being moderately sensitive, and tier 3 being the least sensitive to NAbs (Mascola et al., J Virol 2005; 79:10103-7). He...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2013.05.024

    authors： Coleman JK,Pu R,Martin MM,Noon-Song EN,Zwijnenberg R,Yamamoto JK

    更新日期：2014-02-03 00:00:00

  • Developing an HPV vaccine to prevent cervical cancer and genital warts.

    abstract：:The challenges of the journey from target identification through development of a prophylactic quadrivalent human papillomavirus (HPV) vaccine have been met in Gardasil. Cervical cancer is the second leading cause of cancer-related death in women worldwide. Approximately 70% of cervical cancer is caused by infection w...

    journal_title：Vaccine

    pub_type： 杂志文章,评审

    doi：10.1016/j.vaccine.2007.01.013

    authors： Bryan JT

    更新日期：2007-04-20 00:00:00

  • Changes in serotype distribution of Haemophilus influenzae meningitis isolates identified through laboratory-based surveillance following routine childhood vaccination against H. influenzae type b in Brazil.

    abstract：:Following routine childhood vaccination against Haemophilus influenzae type b (Hib) disease in Brazil in 1999, passive laboratory surveillance reported increasing numbers of non-b serotypes and nontypeable H. influenzae (NTHi) from meningitis cases. To characterize this increase, we analyzed data on 3910 H. influenzae...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2011.09.053

    authors： Zanella RC,Bokermann S,Andrade AL,Flannery B,Brandileone MC

    更新日期：2011-11-08 00:00:00

  • Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older.

    abstract：:A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608-a newly developed live-attenuated zoster vaccine in Korea-relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were e...

    journal_title：Vaccine

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.vaccine.2019.04.046

    authors： Choi WS,Choi JH,Jung DS,Choi HJ,Kim YS,Lee J,Jang HC,Shin EC,Park JS,Kim H,Cheong HJ

    更新日期：2019-06-12 00:00:00

  • Pneumococcal pneumonia in the UK--how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV).

    abstract：:This study examines the potential clinical and economic benefits for adults arising from paediatric pneumococcal vaccination in the UK. A UK birth cohort model with a 10-year horizon and using a primary 4-dose paediatric 7-valent pneumococcal conjugate vaccine (PCV) schedule was populated with 1999 morbidity and morta...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2004.08.051

    authors： McIntosh ED,Conway P,Willingham J,Hollingsworth R,Lloyd A

    更新日期：2005-02-25 00:00:00

  • Relating cognitive function to military aviator performance in early HIV infection.

    abstract：:There has been controversy about whether cognitive changes occur in early human immunodeficiency virus (HIV) disease. In those studies reporting cognitive changes, these are typically subclinical, and their relationship to daily and/or occupational functioning has not been addressed. The potential effects of changes m...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/0264-410x(93)90231-l

    authors： Mapou RL,Rundell JR,Kay GG,Tramont EC

    更新日期：1993-01-01 00:00:00

  • Vaccinia virus proteins activate human dendritic cells to induce T cell responses in vitro.

    abstract：:The mechanisms of protection elicited by smallpox vaccine in humans have not been delineated. Dendritic cells (DCs) are the most potent of professional antigen presenting cells which on activation modulate both innate and adaptive immune responses. Immunogenic proteins of vaccinia virus have been identified with prote...

    journal_title：Vaccine

    pub_type： 杂志文章

    doi：10.1016/j.vaccine.2008.10.031

    authors： Agrawal S,Gupta S,Agrawal A

    更新日期：2009-01-01 00:00:00